Benitec Biopharma Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Benitec Biopharma Inc. (BNTC) reported Cash and Cash Equivalents, Period Increase (Decrease) of $2.19 million for the 9-month period ending 2021-03-31, per its 10-Q filed 2021-05-12.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2021-05-12
- Benitec Biopharma Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-03-31 was -$2.02M.
- Benitec Biopharma Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-03-31 was -$2.39M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month |
|---|---|---|---|
| 2021-03-31 | -$2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-12 | $2.19M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $4.21M 10-Q · filed 2021-02-09 | ||
| 2020-03-31 | -$2.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-12 | -$4.32M 10-Q · filed 2021-05-12 | |
| 2019-12-31 | -$1.93M 10-Q · filed 2021-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |